WuXi Biologics (original) (raw)

dbo:abstract

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites around the world including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore with a planned total production capacity of 220,000 by 2022 and over 430,000 liters by 2023. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. (en)
药明生物技术有限公司（英語：WuXi Biologics (Cayman) Inc., 港交所：2269），是一家中国生物技术公司，董事长是李革，首席执行官是。 (zh)

dbo:assets

1.28961E10 (dbd:renminbi)
2.0899396E10 (dbd:renminbi)

dbo:equity

1.28961E10 (dbd:renminbi)
2.0899396E10 (dbd:renminbi)

dbo:foundingYear

2015-01-01 (xsd:gYear)

dbo:location

dbo:netIncome

1.6927E9 (dbd:renminbi)

dbo:numberOfEmployees

6348 (xsd:nonNegativeInteger)

dbo:revenue

3.983687E9 (dbd:renminbi)
5.6124E9 (dbd:renminbi)

dbo:thumbnail

wiki-commons:Special:FilePath/Logo_of_WuXi_Biologics.png?width=300

dbo:type

dbr:Public_company

dbo:wikiPageExternalLink

https://www.wuxibiologics.com

dbo:wikiPageID

61516243 (xsd:integer)

dbo:wikiPageLength

19120 (xsd:nonNegativeInteger)

dbo:wikiPageRevisionID

1115414321 (xsd:integer)

dbo:wikiPageWikiLink

dbp:areaServed

Worldwide (en)

dbp:assets

(en)
1.28961E10 (dbd:renminbi)
2.0899396E10 (dbd:renminbi)

dbp:bloomberg

2269 (xsd:integer)

dbp:equity

(en)
1.28961E10 (dbd:renminbi)
2.0899396E10 (dbd:renminbi)

dbp:founded

in Wu Xi City, China (en)

dbp:google

HKG:+2269 (en)

dbp:imageCaption

WuXi Biologics Headquarters in Shanghai (en)

dbp:imageSize

250 (xsd:integer)

dbp:industry

dbp:isin

KYG970081173 (en)

dbp:location

Primary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092 (en)

dbp:logo

Logo of WuXi Biologics.png (en)

dbp:name

WuXi Biologics (en)

dbp:netIncome

(en)
1.010337E9 (dbd:renminbi)
1.6927E9 (dbd:renminbi)

dbp:numEmployees

6348 (xsd:integer)

dbp:numEmployeesYear

2020 (xsd:integer)

dbp:reuters

2269 (xsd:integer)

dbp:revenue

(en)
3.983687E9 (dbd:renminbi)
5.6124E9 (dbd:renminbi)

dbp:subsid

CMAB Biopharma Group (en)
WuXi Vaccines (en)

dbp:symbol

2269 (xsd:integer)

dbp:tradedAs

dbr:Hang_Seng_Index
SEHK:2269 (en)

dbp:type

dbr:Public_company

dbp:website

https://www.wuxibiologics.com

dbp:wikiPageUsesTemplate

dbp:yahoo

2269 (xsd:integer)

dct:subject

dbc:Pharmaceutical_companies_of_China

rdf:type

rdfs:comment

药明生物技术有限公司（英語：WuXi Biologics (Cayman) Inc., 港交所：2269），是一家中国生物技术公司，董事长是李革，首席执行官是。 (zh)
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. (en)

rdfs:label

WuXi Biologics (en)
药明生物 (zh)

owl:sameAs

prov:wasDerivedFrom

wikipedia-en:WuXi_Biologics?oldid=1115414321&ns=0

foaf:depiction

foaf:homepage

https://www.wuxibiologics.com

foaf:isPrimaryTopicOf

wikipedia-en:WuXi_Biologics

foaf:name

WuXi Biologics (en)

is dbo:wikiPageWikiLink of

is foaf:primaryTopic of

wikipedia-en:WuXi_Biologics